Gain Therapeutics, Inc. (GANX)
NASDAQ: GANX · Real-Time Price · USD
2.070
-0.250 (-10.78%)
At close: Nov 4, 2024, 4:00 PM
2.100
+0.030 (1.45%)
After-hours: Nov 4, 2024, 5:11 PM EST
Gain Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Gain Therapeutics stock have an average target of 7.75, with a low estimate of 6.00 and a high estimate of 9.00. The average target predicts an increase of 274.40% from the current stock price of 2.07.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for GANX stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '24 | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 2 |
| Buy | 1 | 1 | 1 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 5 | 5 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +286.47% | Oct 9, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +286.47% | Oct 1, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +286.47% | Sep 3, 2024 |
| Oppenheimer | Oppenheimer | Buy Initiates $8 | Buy | Initiates | $8 | +286.47% | Aug 14, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $6 | Strong Buy | Maintains | $6 | +189.86% | Aug 9, 2024 |
Financial Forecast
Revenue This Year
34.00K
from 55.18K
Decreased by -38.39%
Revenue Next Year
136.00K
from 34.00K
Increased by 300.03%
EPS This Year
-1.07
from -1.71
EPS Next Year
-0.91
from -1.07
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 105,000 | 420,000 | n/a | ||
| Avg | 33,997 | 135,997 | n/a | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 90.3% | 1,135.4% | - | ||
| Avg | -38.4% | 300.0% | - | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.06 | -0.75 | -1.48 | ||
| Avg | -1.07 | -0.91 | -1.44 | ||
| Low | -1.06 | -1.13 | -1.38 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.